KaydedilenlerDerginizi ekleyin

Dergiler / Üroonkoloji Bülteni / 2019 / Cilt: 18 - Sayı: 1

The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors

Önder ÇINAR
N. Aydın MUNGAN
Sayfa
30–33
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although findings are insufficient, promising results have been reported regarding circulating miR-21 as a biomarker for BC prospective studies with larger numbers of participants are needed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Bladder cancer (BC) is one of the commonly diagnosed urological cancers that causes human death, ranked as the seventh most common cancer worldwide.
📊
Temel Bulgular & Veri:The purpose of this study was to evaluate the diagnostic role and prognostic significance of microRNA-21 (miR-21) in non-muscle invasive bladder tumors.
💡
Sonuç & Katkı:Although findings are insufficient, promising results have been reported regarding circulating miR-21 as a biomarker for BC prospective studies with larger numbers of participants are needed.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Bladder cancer (BC) is one of the commonly diagnosed urological cancers that causes human death, ranked as the seventh most common cancer worldwide. To date, no reliable diagnostic tool has been defined to recognize non-muscle invasive bladder tumors other than cystoscopy. For this reason, scientists have focused on finding new non-invasive biomarkers that can be used to diagnose BC with higher specificity and sensitivity. The purpose of this study was to evaluate the diagnostic role and prognostic significance of microRNA-21 (miR-21) in non-muscle invasive bladder tumors. In this review, the overall diagnostic performance of miR-21 was discussed on non-invasive BC based on a literature search of PubMed and Cochrane Library. Although findings are insufficient, promising results have been reported regarding circulating miR-21 as a biomarker for BC prospective studies with larger numbers of participants are needed.

🔖

Bu Makaleye Atıf Yap

ÇINAR, Ö., MUNGAN, N. A. (2019). The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni, Cilt: 18 - Sayı: 1, 30–33. https://ajindex.com/articles/334380

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. V1.0. International Agency for Research on Cancer 2012.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
  3. Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 2015;29:177-189.
  4. Chavan S, Bray F, Lortet-Tieulent J, et al. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
  5. Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014;51:291-304.
  6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
  7. Matsuda T, Hori M. Five-year relative survival rate of bladder cancer in the USA, Europe and Japan. Jpn J Clin Oncol 2014;44:776. Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther 2013;17:71-84.
  8. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-249.
  9. Arcangeli G, Arcangeli S, Strigari L. A systematic review and metaanalysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015;94:105-115. Messing EM. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2007. p. 2426-2427.
  10. Smith ZL, Guzzo TJ. Urinary markers for bladder cancer. F1000Prime Rep 2013;5:21. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010;36:195-205.
  11. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki- 67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-760.
  12. Quan C, Park MS, Jo SW, et al. Effects of transforming growth factor-beta1 and its receptor on the development, recurrence and progression of human bladder cancer. Korean J Urol 2006;47:426-435.
  13. Ha YS, Yun SJ, Kim YJ, et al. Utility of Smo as a prognostic marker for human bladder tumors. Korean J Urol 2007;48:997-1003. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;22(Suppl 2):53-59.
  14. Nakamura K, Kasraeian A, Iczkowski KA, et al. Utility of serial urinary cytology in the initial evaluation of t